Pregnancy and Child Health Research Center, HealthPartners Institute, Minneapolis, Minnesota; Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada.
Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada.
Am J Prev Med. 2024 Apr;66(4):672-680. doi: 10.1016/j.amepre.2023.11.008. Epub 2023 Nov 14.
The COVID-19 pandemic resulted in changes in prescription patterns and fillings for certain medications, but little is known about its impact on the dispensing of cardiovascular drugs.
Trends in dispensing of cardiovascular drugs before and during the pandemic were examined using a population-based cohort in Norway. Using interrupted time series analyses and considering March 1, 2020 as the interruption point, the impact of the pandemic on defined daily dose dispensing of prescribed cardiovascular drugs was estimated in a population of adults with and without pre-existing cardiovascular disease from January 2018 to December 2021. All data were analyzed in 2023.
In a total of 4,053,957 adults, 690,910 (17.0%) had pre-existing cardiovascular disease. Prior to the pandemic, there was a significant monthly increase in any cardiovascular drug dispensing among those with pre-existing cardiovascular disease (0.30 defined daily dose per month per adult), including prescription of diuretics, calcium channel blockers, and lipid-modifying agents. After controlling for preinterruption trends, there was a slight decrease in level change immediately after the start of the pandemic (2.5 defined daily dose per month per adult) but an increase in the postinterruption trend (0.06 defined daily dose per month per adult) for dispensing of cardiovascular prescriptions, although these changes were not significant.
Although the COVID-19 pandemic did not appear to result in significant changes in patterns of cardiovascular drug dispensing in Norway, continued access to cardiovascular drugs remains important to prevent further related morbidity.
COVID-19 大流行导致某些药物的处方模式和配药发生变化，但对于其对心血管药物配药的影响知之甚少。
使用挪威的基于人群的队列，检查大流行前后心血管药物配药的趋势。使用中断时间序列分析，并将 2020 年 3 月 1 日作为中断点，估计大流行对 2018 年 1 月至 2021 年 12 月期间患有和不患有心血管疾病的成年人的预定心血管药物的定义日剂量配药的影响。所有数据均在 2023 年进行分析。
在总共 4053957 名成年人中，有 690910 人（17.0%）患有先前存在的心血管疾病。在大流行之前，患有先前存在的心血管疾病的患者中，任何心血管药物的配药每月都呈显著增加趋势（每个成年人每月 0.30 个定义日剂量），包括利尿剂、钙通道阻滞剂和血脂调节剂的处方。在控制中断前趋势后，大流行开始后立即出现的水平变化略有下降（每个成年人每月 2.5 个定义日剂量），但中断后趋势增加（每个成年人每月 0.06 个定义日剂量），尽管这些变化并不显著。
尽管 COVID-19 大流行似乎并未导致挪威心血管药物配药模式发生重大变化，但继续获得心血管药物对于预防进一步相关发病率仍然很重要。
